{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03217032",
      "OrgStudyIdInfo": {
        "OrgStudyId": "GIMI-IRB-17007"
      },
      "Organization": {
        "OrgFullName": "Shenzhen Geno-Immune Medical Institute",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Lentiviral FVIII Gene Therapy",
      "OfficialTitle": "Lentiviral FVIII Gene Therapy for Hemophilia A"
    },
    "StatusModule": {
      "StatusVerifiedDate": "May 2019",
      "OverallStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "June 1, 2020",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "May 31, 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 1, 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "July 3, 2017",
      "StudyFirstSubmitQCDate": "July 11, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 13, 2017",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "May 21, 2019",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "May 23, 2019",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Lung-Ji Chang",
        "ResponsiblePartyInvestigatorTitle": "President",
        "ResponsiblePartyInvestigatorAffiliation": "Shenzhen Geno-Immune Medical Institute"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Shenzhen Geno-Immune Medical Institute",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This study is a Phase I trial using an advanced lentiviral vector to deliver a functional gene for human clotting factor VIII into patients with hemophilia A, to evaluate the safety and efficacy of infusion of lentiviral gene modified autologous stem cells in patients.",
      "DetailedDescription": "Hemophilia A is a genetic bleeding disorder caused by the lack of ability to produce blood-clotting factor VIII (FVIII). Individuals with hemophilia A suffer repeated bleeding episodes, which can cause chronic joint disease and sometimes even death due to the inability for blood to clot efficiently. The current treatment is intravenous infusion of clotting factor concentrates, either prophylactically or in response to bleeding. The procedure is life time long and expensive while still cannot achieve a cure.Gene therapy is a novel technology that has been successfully demonstrated in a number of clinical studies for diseases such as cancer and genetic diseases. In this study, an advanced lentiviral vector system NHP/TYF will be used to deliver a functional FVIII gene to overcome human clotting FVIII gene defect in patients with hemophilia A. This study is a Phase I trial evaluating the safety and efficacy for infusion of gene modified autologous stem cells in patients with hemophilia A."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Hemophilia A"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Hemophilia A",
          "factor VIII",
          "Gene therapy",
          "lentiviral vector"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "10",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "YUVA-GT-F801",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Gene transfer to treat Hemophilia A",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: YUVA-GT-F801"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "YUVA-GT-F801",
            "InterventionDescription": "Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "YUVA-GT-F801"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of participants experiencing drug-related adverse events",
            "PrimaryOutcomeDescription": "As assessed by physical exam, vital signs, standard clinical labs, and Bethesda assay for FVIII inhibitor",
            "PrimaryOutcomeTimeFrame": "a year"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Changes from baseline in circulating FVIII activity (IU/dL or % normal)",
            "SecondaryOutcomeTimeFrame": "a year"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAble to provide informed consent and comply with requirements of the study.\nMales ≥2 years with confirmed diagnosis of hemophilia A (endogenous factor VIII ≤2 IU/dL or ≤2% of normal).\nA minimum average of 4 bleeding events per year requiring episodic treatment of factor VIII infusions or prophylactic factor VIII infusions.\nNo measurable factor VIII inhibitor as assessed by the central laboratory and have no prior history of inhibitors to factor VIII protein.\nAgree to use reliable barrier contraception until 3 consecutive samples are negative for vector sequences.\n\nExclusion Criteria:\n\nSignificant liver dysfunction as defined by abnormal alanine transaminase, bilirubin and alkaline phosphatase.\nHistory of inhibitor against factor VIII.\nEvidence of active hepatitis B or C and currently on antiviral therapy.\nHave serological evidence of HIV-1 or HIV-2 with CD4 counts ≤200/mm3 (subjects who are HIV+ and stable with CD4 count >200/mm3 and undetectable viral load are eligible to enroll).\nAny evidence of active infection or any immunosuppressive disorder.\nParticipated in a gene transfer trial within the last 6 months or in a clinical trial with an investigational drug within the last 12 weeks.\nUnable or unwilling to comply with study assessments.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "2 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Lung-Ji Chang, PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "86-075586725195",
            "CentralContactEMail": "c@szgimi.org"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Lung-Ji Chang",
            "OverallOfficialAffiliation": "Shenzhen Geno-Immune Medical Institute",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Shenzhen Geno-immune Medical Institute",
            "LocationCity": "Shenzhen",
            "LocationState": "Guangdong",
            "LocationZip": "518000",
            "LocationCountry": "China"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006467",
            "ConditionMeshTerm": "Hemophilia A"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000025861",
            "ConditionAncestorTerm": "Blood Coagulation Disorders, Inherited"
          },
          {
            "ConditionAncestorId": "D000001778",
            "ConditionAncestorTerm": "Blood Coagulation Disorders"
          },
          {
            "ConditionAncestorId": "D000006402",
            "ConditionAncestorTerm": "Hematologic Diseases"
          },
          {
            "ConditionAncestorId": "D000020147",
            "ConditionAncestorTerm": "Coagulation Protein Disorders"
          },
          {
            "ConditionAncestorId": "D000006474",
            "ConditionAncestorTerm": "Hemorrhagic Disorders"
          },
          {
            "ConditionAncestorId": "D000030342",
            "ConditionAncestorTerm": "Genetic Diseases, Inborn"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M8705",
            "ConditionBrowseLeafName": "Hemophilia A",
            "ConditionBrowseLeafAsFound": "Hemophilia A",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21130",
            "ConditionBrowseLeafName": "Hemostatic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4211",
            "ConditionBrowseLeafName": "Blood Coagulation Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22248",
            "ConditionBrowseLeafName": "Blood Coagulation Disorders, Inherited",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8642",
            "ConditionBrowseLeafName": "Hematologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21135",
            "ConditionBrowseLeafName": "Coagulation Protein Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8712",
            "ConditionBrowseLeafName": "Hemorrhagic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22839",
            "ConditionBrowseLeafName": "Genetic Diseases, Inborn",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2710",
            "ConditionBrowseLeafName": "Hemophilia",
            "ConditionBrowseLeafAsFound": "Hemophilia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T2711",
            "ConditionBrowseLeafName": "Hemophilia A",
            "ConditionBrowseLeafAsFound": "Hemophilia A",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC16",
            "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M7464",
            "InterventionBrowseLeafName": "Factor VIII",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Coag",
            "InterventionBrowseBranchName": "Coagulants"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}